查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601160

胰臟癌治療市場：按類型、產品和最終用戶分類 - 全球預測 2025-2030

Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胰臟癌治療市場規模為46.7億美元，預計2024年將達51.4億美元，複合年成長率為9.95%，預計2030年將達90.9億美元。

胰臟癌治療市場是腫瘤學領域的重要組成部分，專注於開拓胰臟惡性細胞的治療方法。這個市場的範圍正在擴展到標靶治療、化療、放射線治療、免疫治療和基因治療等新選擇。該市場的成長是由胰臟癌盛行率上升、人口老化、意識增強以及醫學研究的進步所推動的。對這些療法的需求源於與胰腺癌相關的歷史上較低的生存率以及改善患者預後的創新療法的迫切需求。典型的最終用戶包括醫院、癌症研究中心和參與研究的製藥公司。

主要市場統計
基準年[2023] 46.7億美元
預測年份 [2024] 51.4億美元
預測年份 [2030] 90.9億美元
複合年成長率（%） 9.95%

影響市場的主要成長要素包括診斷程序的技術進步、強大的藥物管道、不斷增加的研發投資以及政府支持癌症研究的措施。此外，生物技術公司和研究機構之間的合作正在創造潛在的機會，特別是在個人化醫療和生物標記發現方面。利用這些機會的建議包括建立策略夥伴關係、專注於精準醫療等利基領域，以及加速有前景的治療方法的臨床試驗。

然而，這個市場面臨著治療成本高、監管核准嚴格以及早期診斷挑戰等限制，影響了患者獲得治療的機會。競爭對手之間的敵對關係以及藥物開發上的大量時間投入構成了額外的障礙。公司可以透過將研究重點放在開發微創治療方法、改進藥物輸送系統和探索新的聯合治療來推動創新。此外，還有望利用人工智慧和巨量資料分析來提高藥物發現效率。

總之，雖然胰臟癌藥物市場透過技術進步和合作擁有巨大的成長機會，但解決成本障礙和監管挑戰至關重要。治療創新和資料主導的方法將為重大突破鋪平道路，推動業務成長並改善患者照護。

市場動態：快速發展的胰臟癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變胰臟癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球胰臟癌盛行率不斷上升
    • 政府努力擴大胰臟癌治療選擇
  • 市場限制因素
    • 由於副作用而難以獲得藥物召回和報銷選項
  • 市場機會
    • 提高胰臟癌藥物療效的研究措施和進展
    • 核准胰臟癌治療和核准罕見癌症藥物
  • 市場挑戰
    • 胰臟癌治療方案的局限性和併發症以及缺乏訓練有素的醫療專業人員

波特五力：駕馭胰臟癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解胰臟癌藥物市場的外部影響

外部宏觀環境因素在塑造胰臟癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解胰臟癌治療藥物市場的競爭狀況

胰臟癌治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣胰臟癌治療市場供應商的績效評估

FPNV定位矩陣是評估胰臟癌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球胰臟癌發生率正在上升
      • 政府努力擴大胰臟癌治療選擇
    • 抑制因素
      • 難以獲得危險藥品召回和報銷選擇
    • 機會
      • 提高胰臟癌藥物療效的研究舉措和進展
      • 核准胰臟癌藥物和核准用於癌症治療的孤兒藥
    • 任務
      • 胰臟癌治療方案的局限性和併發症以及缺乏訓練有素的醫療專業人員
  • 市場區隔分析
    • 類型：外分泌胰臟癌的快速進展需要快速部署治療方案
    • 產品：擴大核准的化療方案的數量
    • 最終用途：擴大胰臟癌治療研究機構之間的合作與研發活動
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章胰臟癌治療藥物市場：依類型

  • 內分泌胰臟癌
  • 外分泌胰臟癌

第7章胰臟癌治療藥物市場：依產品

  • 化療
  • 基因治療
  • 免疫療法
  • 放射治療
  • 外科手術
  • 標靶治療

第8章胰臟癌治療藥物市場：依最終用途分類

  • 癌症中心/診所
  • 醫院
  • 調查機構

第9章美洲胰臟癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區胰臟癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲胰臟癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Trishula Therapeutics 開始在第一線轉移性胰臟癌患者中進行抗 CD39 抗體 TTX-030 的 2 期試驗
    • Risata 獲得治療胰臟癌的孤兒藥資格
    • PanCAN 宣布新的高級研究投資
    • Prestige Biopharma 與 Imagion Biosystems 簽署合作協議，開發胰臟癌早期診斷平台
    • TriSalus Life Sciences 完成與 MedTech Acquisition Corporation 的合併
    • 百時美施貴寶透過收購 Mirati Therapeutics 加強腫瘤學產品組合併使其多元化
    • 安斯泰來製藥 ( Astellas Pharma) 和 Poseida Therapeutics 宣布策略性投資，支持 Poseida 革新癌細胞療法的努力
    • FDA 指定 Zenocutuzumab 突破性治療 NRG1+ 胰臟癌
    • FDA核准TME Pharma 胰臟癌治療試驗的 IND
    • GenesisCare 在 Lee Health 區域癌症中心安裝 ViewRay MRIdian MRI 導引放射治療系統
    • 國家撥款 300 萬美元用於胰臟癌研究
    • Leap Therapeutics 收購 Flame Biosciences
    • Caladrius Biosciences 和 Cend Therapeutics 宣布完成合併並組成 Lisata Therapeutics
    • Fes Therapeutics 融資 4700 萬美元用於推進癌症臨床試驗
    • Astra Zeneca-默克公司的LYNPARZA獲得歐盟核准用於胰臟癌治療

公司名單

  • Abbvie Inc.
  • Amgen Inc.
  • Ascentage Pharma Group
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Carl Zeiss AG
  • Carrick Therapeutics Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Faeth Therapeutics, Inc.
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • GenesisCare
  • GlaxoSmithKline PLC
  • Hetero Healthcare Limited
  • ImmunityBio, Inc.
  • Innovent Biologics Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mitsubishi Heavy Industries, Ltd.
  • NGM Biopharmaceuticals, Inc.
  • NovalGen
  • Novartis AG
  • PanTher Therapeutics, Inc.
  • Pfizer, Inc.
  • RenovoRx, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zentalis Pharmaceuticals, Inc.
Product Code: MRR-4342CA32667F

The Pancreatic Cancer Therapeutics Market was valued at USD 4.67 billion in 2023, expected to reach USD 5.14 billion in 2024, and is projected to grow at a CAGR of 9.95%, to USD 9.09 billion by 2030.

The pancreatic cancer therapeutics market is a critical segment of the oncology sector, focused on developing treatments that target malignant cells in the pancreas. The scope of this market extends to targeted therapies, chemotherapy, radiation therapy, and emerging options such as immunotherapy and gene therapy. This market's growth is driven by the rising prevalence of pancreatic cancer, an aging population, increased awareness, and advancements in medical research. The necessity of these therapeutics stems from the historically low survival rate associated with pancreatic cancer and the urgent need for innovative treatments that improve patient outcomes. Major end-users include hospitals, cancer research centers, and pharmaceutical companies involved in R&D.

KEY MARKET STATISTICS
Base Year [2023] USD 4.67 billion
Estimated Year [2024] USD 5.14 billion
Forecast Year [2030] USD 9.09 billion
CAGR (%) 9.95%

Key growth factors influencing the market include technological advances in diagnostic procedures, a robust pipeline of drugs, increasing investments in R&D, and government initiatives supporting cancer research. Additionally, collaborations between biotechnology firms and research institutions are creating potential opportunities, especially in personalized medicine and biomarker discovery. Recommendations to capitalize on these opportunities involve strategic partnerships, focusing on niche segments such as precision medicine, and accelerating clinical trials for promising therapies.

However, the market faces limitations such as high treatment costs, stringent regulatory approvals, and challenges in early diagnosis, which impact patient access to therapies. Competitive rivalry and significant time investments in drug development pose further hurdles. Firms can drive innovation by concentrating research efforts on developing less invasive treatments, improving drug delivery systems, and exploring novel combination therapies. Moreover, leveraging AI and big data analytics to enhance drug discovery efficiency is promising.

In conclusion, while the pancreatic cancer therapeutics market offers substantial opportunities for growth through technological advancements and collaborative efforts, addressing cost barriers and regulatory challenges will be crucial. Innovation in treatment modalities and data-driven approaches will pave the way for significant breakthroughs, facilitating business growth and improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pancreatic Cancer Therapeutics Market

The Pancreatic Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of pancreatic cancer cases across the world
    • Government initiatives to expand access to pancreatic cancer treatment options
  • Market Restraints
    • Adverse drug recalls and difficulty in availing reimbursement options
  • Market Opportunities
    • Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
    • Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
  • Market Challenges
    • Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the Pancreatic Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pancreatic Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pancreatic Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pancreatic Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pancreatic Cancer Therapeutics Market

A detailed market share analysis in the Pancreatic Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pancreatic Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pancreatic Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Endocrine Pancreatic Cancer and Exocrine Pancreatic Cancer.
  • Based on Product, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on End-Use, market is studied across Cancer Centers/Clinics, Hospitals, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
      • 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
      • 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
    • 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
    • 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pancreatic Cancer Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Endocrine Pancreatic Cancer
  • 6.3. Exocrine Pancreatic Cancer

7. Pancreatic Cancer Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Gene Therapy
  • 7.4. Immunotherapy
  • 7.5. Radiation Therapy
  • 7.6. Surgery
  • 7.7. Targeted Therapy

8. Pancreatic Cancer Therapeutics Market, by End-Use

  • 8.1. Introduction
  • 8.2. Cancer Centers/Clinics
  • 8.3. Hospitals
  • 8.4. Research Institutes

9. Americas Pancreatic Cancer Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Pancreatic Cancer Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
    • 12.3.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
    • 12.3.3. PanCAN Announces New & Advanced Research Investment
    • 12.3.4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
    • 12.3.5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
    • 12.3.6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
    • 12.3.7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
    • 12.3.8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
    • 12.3.9. FDA Clears TME Pharma's IND for Pancreatic Cancer Therapy Trial
    • 12.3.10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
    • 12.3.11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
    • 12.3.12. Leap Therapeutics Acquires Flame Biosciences
    • 12.3.13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
    • 12.3.14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
    • 12.3.15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Amgen Inc.
  • 3. Ascentage Pharma Group
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bristol-Myers Squibb Company
  • 7. C.H. Boehringer Sohn AG & Co. KG
  • 8. Carl Zeiss AG
  • 9. Carrick Therapeutics Limited
  • 10. Cipla Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. Faeth Therapeutics, Inc.
  • 15. FUJIFILM Holdings Corporation
  • 16. GE HealthCare Technologies, Inc.
  • 17. GenesisCare
  • 18. GlaxoSmithKline PLC
  • 19. Hetero Healthcare Limited
  • 20. ImmunityBio, Inc.
  • 21. Innovent Biologics Inc.
  • 22. Johnson & Johnson Services, Inc.
  • 23. Lupin Limited
  • 24. Merck & Co., Inc.
  • 25. Mitsubishi Heavy Industries, Ltd.
  • 26. NGM Biopharmaceuticals, Inc.
  • 27. NovalGen
  • 28. Novartis AG
  • 29. PanTher Therapeutics, Inc.
  • 30. Pfizer, Inc.
  • 31. RenovoRx, Inc.
  • 32. Sun Pharmaceutical Industries Ltd.
  • 33. Teva Pharmaceutical Industries Ltd.
  • 34. Zentalis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. PANCREATIC CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PANCREATIC CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PANCREATIC CANCER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY ENDOCRINE PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY EXOCRINE PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023